Insider · CIK 0001240499
Sharon Barbari
Files at YARW (VYNE Therapeutics Inc.). First filing -, latest -.
In brief
Sharon Barbari files SEC Form 4 as director at YARW (VYNE Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sharon Barbari has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2025 |
| Dec 12, 2024 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Dec 13, 2023 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2023 |
Questions about Sharon Barbari
Answered from the filings on this page, as of the latest one.
Is Sharon Barbari buying or selling?
Sharon Barbari has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sharon Barbari's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sharon Barbari has 0.
Where does Sharon Barbari file Form 4?
Sharon Barbari has filed Form 4 at YARW (VYNE Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.